Iseki & Co (OTC:ISKIF) Stock, Quote.Headers.trade-ideas

Iseki & Co Ltd is a manufacturer of agricultural machinery in Japan whose products include cultivating machinery comprising tractors, multipurpose vehicles, and tillers; planting machinery, including rice and vegetable transplanters; and harvesting machinery consisting of combine harvesters and binders. The company distributes its products within domestic market and to overseas markets through its distribution network.

Iseki & Co Ltd

Roth MKM analyst Matt Koranda downgrades Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) from Buy to Neutral and maintains the price target from $42 to $42.

News

Downgrades

Price Target

Analyst Ratings

VSTO

Roth MKM Downgrades Vista Outdoor to Neutral, Maintains Price Target to $42

Biotech

Health Care

General

BTAI

Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure

Roth MKM analyst Scott Fortune initiates coverage on Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announces Price Target of $50.

Initiation

Roth MKM Initiates Coverage On Turning Point Brands with Buy Rating, Announces Price Target of $50

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Announced That Data From Its Nomlabofusp Phase 1 Studies And Phase 2 Dose Exploration Study, Some Of Which Has Been Previously Disclosed, Will Be Presented At The Annual International Congress For Ataxia Research

HC Wainwright &amp; Co. analyst Robert Burns upgrades Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) from Neutral to Buy and announces $5 price target.

Upgrades

PRLD

HC Wainwright & Co. Upgrades Prelude Therapeutics to Buy, Announces $5 Price Target

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Commodities

Legal

Markets

TUSK

Cobra Acquisitions, A Subsidiary Of Mammoth Energy Services, Announced That The Previously Disclosed Settlement Agreement With The Puerto Rico Electric Power Authority Was Approved By The Title III Court, PREPA Required To Pay Cobra $150M Within Ten Business Days

<ul>
<li>One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers.&nbsp;</li>
<li>Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.&nbsp;</li>
<li>The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.</li>
</ul>

GLMD

Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years

B. Riley Securities initiates coverage on Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy rating and announces Price Target of $33.

CNTA

B. Riley Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $33

COEP

Coeptis Therapeutics Receives Notification Letter From Nasdaq Hearings Panel Granting Its Request For Continued Listing Through January 15, 2025

SYTA

Siyata Mobile Announced That Its SD7 Handsets And VK7 Vehicle Kits Were Purchased And Deployed By A New Customer, Trans-west Security Systems

Raymond James analyst Stephen Laws upgrades Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) from Market Perform to Outperform and announces $34 price target.

SAFE

Raymond James Upgrades Safehold to Outperform, Announces $34 Price Target

SpaceX CEO Elon Musk said on Thursday that the rocket manufacturing company intends to <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights">offer a trip to Mars</a> to anyone who volunteers in the future but warned that the journey might be uncomfortable.
What Happened: &#8220;In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go&#8230;&#8221; Musk wrote on social media platform X in response to former European Union Commissioner Thierry Breton with whom he has a history of sparring now and then.
However, the journey to Mars, Musk warned, will be like a &#8220;long sea voyage.&#8221;
&#8220;&#8230;.it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure!&#8221; Musk said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go, bearing in mind that it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure! Becoming multiplanetary ensures the long-term survival of life.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1836705091446853687?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk aims to take humans to Mars with SpaceX&#8217;s Starship launch vehicle in an attempt to &#8220;make life multi-planetary.&#8221; Musk has previously even envisioned a self-sustaining city on Mars called Terminus.
Why It Matters: Earlier this month, Musk said the first Starships will <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights" target="_blank" rel="noreferrer noopener">head to Mars in two years</a> once the next Earth-Mars transfer window opens.
The first launches to Mars in 2026, Musk then said, will not have a crew onboard and will be aimed at testing the flight's ability to land intact on Mars.
"If those landings go well, then the first crewed flights to Mars will be in 4 years," Musk wrote, pegging the first crewed Starship flights to the neighboring planet for 2028. A self-sustaining city, he said, should be ready in about 20 years. 
Starship, however, is still under development and undergoing test flights. It was last launched in June and the company is <a href="https://www.benzinga.com/news/24/09/40932353/spacex-continues-to-prepare-for-future-starship-flights-despite-delays-in-faa-launch-clearance-elon">now awaiting the green light </a>from the Federal Aviation Administration for its fifth flight test. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40934031/teamsters-opts-to-not-endorse-either-harris-or-trump-for-upcoming-presidential-elections-citing-fail">Teamsters Opts To Not Endorse Either Harris Or Trump For Upcoming Presidential Elections, Citing Failure To Secure Pledges Of Non-Interference In Union Campaigns</a></li>
</ul>
Image generated using Midjourney and official SpaceX photos on Flickr

SPACE

Tech

SpaceX CEO Elon Musk Says Anyone Can Go To Mars With SpaceX But Journey Would Be Like A 'Long Sea Voyage In Centuries Past'

HC Wainwright &amp; Co. analyst Arthur He reiterates Satellos Bioscience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MSCL#TSX">MSCL</a>) with a Buy and maintains C$1.2 price target.

Reiteration

TSX:MSCL

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains C$1.2 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

ACET

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Offerings

Murphy Oil Intends To Offer $600M Of Senior Notes Due 2032

Ahead of the 2024 presidential election, Elon Musk has thrown his support behind Donald Trump, while his employees are reportedly largely backing Kamala Harris, according to recent data.
What Happened: According to OpenSecrets, employees at Tesla Inc. have contributed $42,824 to Harris&#8217; campaign, compared to $24,840 for Trump. Workers at SpaceX have donated $34,526 to Harris, while only $7,652 has gone to Trump. At X, formerly Twitter, employees have given $13,213 to Harris and less than $500 to Trump, Reuters reported on Thursday.
These figures, though relatively small, highlight a political divide between Musk and his workforce. Musk, the world&#8217;s richest man, has promoted Trump on X and criticized left-leaning ideologies as a &#8220;woke-mind virus.&#8221; He did not respond to requests for comment. In 2020, Musk supported President Joe Biden but has since shifted rightward.
Trump has promised to appoint Musk to lead a government efficiency commission if he wins the Nov. 5 election. The OpenSecrets data includes donations from employees, owners, and their immediate family members, as companies themselves cannot donate to federal campaigns.
See Also: <a href="https://www.benzinga.com/news/24/09/40899012/elon-musk-reacts-after-trump-campaign-releases-over-50-examples-of-democrats-rhetoric-that-inspired?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Trump Campaign Releases Over 50 Examples of Democrats&#8217; Rhetoric That &#8216;Inspired Assassination Attempt&#8217;</a>
Many of Musk&#8217;s employees are based in California, a Democratic stronghold, noted Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, a Tesla shareholder and X investor. In July, Musk announced plans to move X and SpaceX headquarters to Texas due to a California gender-identity law, which he called the &#8220;last straw.&#8221; 
Tesla and X have yet to respond to Benzinga&#8217;s queries.
Why It Matters: Musk&#8217;s political stance has evolved significantly over the years. In August, Musk explained his <a href="https://www.benzinga.com/news/24/08/40329702/elon-musk-who-once-queued-for-6-hours-to-shake-obamas-hand-explains-why-hes-now-supporting-trump-my">support for Trump</a>, stating that his track record has been moderate and he has not been particularly political in the past. He revealed this during a conversation with Trump, touching on various topics from immigration to electric vehicles. 
In September, Musk commented on a debate between Trump and Harris, expressing <a href="https://www.benzinga.com/news/24/09/40808912/elon-musk-says-kamala-harris-exceeded-most-peoples-expectations-but-debate-hosts-were-unfair-to-trum">dissatisfaction with the debate hosts</a> and raising concerns about the lack of discussion on the national debt crisis. He also mentioned that Harris exceeded most people&#8217;s expectations during the debate.
Recently, Musk faced backlash for a <a href="https://www.benzinga.com/news/24/09/40890277/elon-musk-says-his-now-deleted-controversial-post-after-latest-trump-assassination-which-was-labeled">controversial post on X</a>, which he later deleted. The post questioned why no one was attempting to assassinate President Joe Biden or Harris, following an assassination attempt on Trump. The White House labeled the post as &#8220;irresponsible.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

TSLA

While Elon Musk Backs Trump For The White House, His Teams At Tesla, X And SpaceX Are Supporting Kamala Harris: Employees Have Reportedly Donated Over $90K To Vice President's Campaign

Raymond James analyst Stephen Laws downgrades NexPoint Real Est Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NREF#NYSE">NREF</a>) from Strong Buy to Market Perform.

NREF

Raymond James Downgrades NexPoint Real Est Finance to Market Perform

This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this devastating neurodegenerative condition.

Financing

TLSA

Tiziana Life Sciences Announced The National Institutes Of Health Have Awarded A $4M Grant To Study Nasal Anti-CD3 For Alzheimer's Disease

Confirmed overall response rate (ORR) was&nbsp;37.5%&nbsp;for pelareorep + paclitaxel and&nbsp;13.3%&nbsp;for paclitaxel.&nbsp;As previously reported, ORRs at week 16 (the trial&#39;s primary endpoint) in the pelareorep + paclitaxel and paclitaxel monotherapy cohorts were&nbsp;31%&nbsp;and&nbsp;20%, respectively.
&quot;The fact that the median overall survival was not reached because more than half the patients were still alive at the end of the study is a remarkable achievement for us,&quot; said&nbsp;Wayne Pisano, Interim CEO and Chair of Oncolytics&#39; Board of Directors.
&nbsp;

ONCY

Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Iseki & Co

Iseki & Co (ISKIF) Forecast

Iseki & Co (OTC:ISKIF) Stock, Quote.Headers.trade-ideas